Novavax, Inc.
NVAXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NVAX. That does not mean none is planned.
Get an email about NVAX's next catalysts
Track Novavax (NVAX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
WebsiteRSV F vaccine with adjuvant
Respiratory Syncytial Virus Infections
SARS-CoV-2 rS antigen/Matrix-M Adjuvant
COVID-19
NVX-CoV2373 + NVX-CoV2540
COVID-19
Bivalent BA.4/5
COVID-19
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)
SARS-CoV Infection
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
COVID-19
NVX-CoV2705 Vaccine
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
RSV-F Vaccine
Respiratory Syncytial Virus (RSV)
Formulation buffer
Respiratory Syncytial Virus Infections
NVX-CoV2515
COVID-19
NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
COVID-19
SARS-CoV-2 rS/Matrix M1-Adjuvant
SARS-CoV-2 Infection
BBIBP-CorV vaccine
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Novavax COVID-19 Vaccine
COVID-19
NVX-CoV2601
COVID-19
Licensed seasonal influenza vaccine
SARS-CoV-2 Infection
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
SARS-CoV Infection
XBB.1.5 Vaccine (Booster)
COVID-19
NVX-CoV2540
COVID-19
Fluzone High Dose
COVID-19
NVX-CoV2373
SARS-CoV-2 Infection
NVX-CoV2373 + NVX-CoV2515
COVID-19
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
SARS-CoV Infection
CIC Vaccine Co-formulated tNIV2, SARSCoV-2 rS and Matrix-M Adjuvant
COVID-19
NanoFlu
Influenza, Human
tNIV Vaccine
COVID-19
Dose 1 of Aluminum Adjuvant
Respiratory Syncytial Virus Infections
cTIV
Influenza
SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
COVID-19
Low dose RSV-F Vaccine without Adjuvant
Respiratory Syncytial Virus (RSV)
High dose RSV F Antigen
Respiratory Syncytial Virus Infections
Dose 2 of Aluminum Adjuvant
Respiratory Syncytial Virus Infections
High dose RSV-F Vaccine with Adjuvant
Respiratory Syncytial Virus (RSV)
SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
SARS-CoV Infection
Matrix-M1™ adjuvant
Influenza (Pandemic)
Fluzone HD - Day 21
Influenza
High dose RSV-F Vaccine without Adjuvant
Respiratory Syncytial Virus (RSV)
RSV F vaccine (injection)
Respiratory Syncytial Virus Infections
SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant
COVID-19
Influenza VLP Vaccine
Influenza
SARS-CoV-2 rS - Phase 1
COVID-19
Quadrivalent VLP Vaccine
Influenza
Influenza VLP Vaccine (recombinant)
Influenza
H5N1 VLP Vaccine
Pandemic Influenza
ICC Vaccine
SARS-CoV Infection
Low dose RSV F Antigen
Respiratory Syncytial Virus Infections
Novavax Quadrivalent vaccine
Influenza
Low dose RSV-F Vaccine with Adjuvant
Respiratory Syncytial Virus (RSV)
qNIV Vaccine with Matrix-M Adjuvant
COVID-19
A/H1N1 2009 Influenza VLP Vaccine
Seasonal Influenza
Monovalent Avian Influenza VLP (H7N9)
Influenza (Pandemic)
RSV F Vaccine with Aluminum Phosphate Adjuvant
Respiratory Syncytial Viruses
Fluzone HD - Day 0
Influenza
SARS-CoV-2 rS/Matrix-M1 Adjuvant
SARS-CoV-2 Infection
NVX-CoV2372
Immunosuppression
SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
COVID-19
RSV F Vaccine
Respiratory Syncytial Viruses
Matrix-M1 Adjuvant
Respiratory Syncytial Viruses
qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant
SARS-CoV Infection
Dose 3 of Aluminum Adjuvant
Respiratory Syncytial Virus Infections
SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
COVID-19
Dose 4 of Aluminum Adjuvant
Respiratory Syncytial Virus Infections
CIC Vaccine with Matrix-M Adjuvant
COVID-19
Novavax Trivalent vaccine
Influenza
Influenza and COVID-19
1 drug in this indication
COVID-19 vaccination
1 drug in this indication
COVID-19
1 drug in this indication
Active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Novavax, Inc.'s drug pipeline?→
CatalystAlert tracks 64 drug candidates in Novavax, Inc.'s (NVAX) pipeline across Phase 3, Phase 2. Its lead program is BBIBP-CorV vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Novavax, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Novavax, Inc. (NVAX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NVAX biotech catalysts?→
Add NVAX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Novavax, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.